Pfizer (NYSE:PFE) Stock Price Down 1.7% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s stock price dropped 1.7% during mid-day trading on Monday . The stock traded as low as $27.81 and last traded at $27.8470. Approximately 25,080,212 shares changed hands during trading, a decline of 45% from the average daily volume of 45,450,879 shares. The stock had previously closed at $28.32.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong oncology franchise and pipeline could support upside around upcoming Q1 results — Pfizer has a deep, multi‑modality oncology portfolio (approved drugs + ADCs, small molecules, immuno‑oncology candidates) that investors view as a durable revenue and growth driver. How Pfizer’s Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: Ongoing R&D activity: Pfizer filed a new Phase 1 study (PF‑07328948), underscoring continued pipeline investment and potential future catalysts beyond established franchises. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Neutral Sentiment: Corporate housekeeping in India (Pfizer Limited) — a special window for dematerialisation of physical shares was announced; limited direct impact on NYSE-listed PFE. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: CEO Albert Bourla’s comments on global research competitiveness highlight strategic priorities but are not an immediate stock mover. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Neutral Sentiment: Sector and index movement are influencing PFE trading — some coverage points to S&P 500 correlation rather than company‑specific drivers. Pfizer Inc. (NYSE:PFE) Market Action Tied To S&P 500 Index Movement
• Negative Sentiment: Analyst pressure: RBC Capital reaffirmed a sell rating on PFE, and at least one analyst reiterated a bearish stance this week — analyst downgrades and negative notes can increase selling pressure. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, a near‑term pipeline disappointment that likely contributed to recent intraday weakness. The same coverage also flags Washington policy risk (reports of potential harsh tariffs on drugmakers without pricing deals) that could pressure margins and sentiment. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Recent price weakness noted across coverage — headlines pointing to PFE declines despite broader market gains highlight investor concern over the items above, amplifying volatility. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. HSBC lifted their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Finally, Barclays began coverage on Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.19.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The business has a 50 day moving average price of $27.14 and a two-hundred day moving average price of $25.89. The company has a market cap of $156.21 billion, a P/E ratio of 20.20 and a beta of 0.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the company posted $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Norges Bank purchased a new position in Pfizer during the 4th quarter valued at about $1,830,986,000. Morgan Stanley increased its holdings in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp increased its holdings in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Franklin Resources Inc. increased its holdings in Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Pfizer by 577.5% during the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after purchasing an additional 7,489,189 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.